Development of an in vitro-based potency assay for anthrax vaccine

Vaccine

Volumn 22, Issue 21-22, 2004, Pages 2843-2852

  Little, S F ^a   Webster, W M ^a   Ivins, B E ^a   Fellows, P F ^a,c   Norris, S L ^b   Andrews, G P ^a  

^a Dept of Immunol and Molec Biology Bldg 1425 U States Army Med R   (United States)

^b Bacteriology Division   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Bacillus anthracis; Potency assay; Vaccine

Indexed keywords

ALLHYDROGEL; ALUMINUM HYDROXIDE; ANTHRAX VACCINE; AVA BIOTHRAX; FREUND ADJUVANT; IMMUNOGLOBULIN G; RECOMBINANT ANTIGEN;

ACTIVE IMMUNIZATION; ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL STRAIN; CAUSE OF DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG FORMULATION; DRUG POTENCY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIG; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROLOGY; STATISTICAL ANALYSIS; SURVIVAL RATE;

ANIMALS; ANTHRAX VACCINES; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HYDROGELS; IMMUNOGLOBULIN G; MICE; MICE, INBRED A; MICE, INBRED BALB C; MICE, INBRED CBA; NEUTRALIZATION TESTS; REFERENCE STANDARDS; VACCINES, SYNTHETIC;

EID: 3142606904     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.12.027     Document Type: Article

References (30)

1. Habig W.H. Potency testing of bacterial vaccines for human use. Vet Microbiol. 37:1993;343-351
2. Arciniega JL, Balls M, van Zeller A-M, Halder ME. editors. Progress in the reduction, refinement and replacement of animal experimentation. What's in a name? The meaning of the term "potency", as applied to immunobiologicals for human use, and its implications for alternatives and validation. Elsevier; 2000. p. 979-86.
3. Baillie L. The development of new vaccines against Bacillus anthracis. J. Appl. Microbiol. 91:2001;609-613
4. Jendrek S., Little S.F., Hem S., Mitra G., Giardina S. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. 21:2003;3011-3018
5. Strange R.E., Belton F.C. Studies on a protective antigen produced in vitro from Bacillus anthracis: purification and chemistry of the antigen. Br. J. Exp. Pathol. 35:1954;153-165
6. -) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immunol. 58:1990;303-308
7. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immunol. 60:1992;662-668
8. Ivins B.E., Pitt M.L.M., Fellows P.F. et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 16(11-12):1998;1141-1148
9. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A.T. Identification of the cellular receptor for anthrax toxin. Nature. 414:2001;225-229
10. Klimpel K.R., Molloy S.S., Thomas G., Leppla S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA. 89:1992;10277-10281
11. Ezzell J.W. Jr., Abshire T.G. Serum protease cleavage of Bacillus anthracis protective antigen. J. Gen. Microbiol. 138:1992;543-549
12. Milne J.C., Furlong D., Hanna P.C., Wall J.S., Collier R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:1994;20607-20612
13. Leppla SH, Alouf JE, Freer JH. editors. Sourcebook of bacterial protein toxins. The anthrax toxin complex, vol. 14. New York: Academic Press; 1991. p. 277-302.
14. Beauregard K.E., Collier R.J., Swanson J.A. Proteolytic activation of receptor-bound anthax protective antigen on macrophages promotes its internalization. Cellular Microbiol. 2(3):2000;251-258
15. Pitt M.L.M., Little S.F., Ivins B.E. et al. In vitro correlate of immunty in a rabbit model of inhalational anthrax. Vaccine. 19:2001;4768-4773
16. Beedham R.J., Turnbull P.C.B., Williamson E.D. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine. 19:2001;4409-4416
17. Kobiler D., Gozes Y., Rosenberg H., Marcus D., Reuveny S., Altboum Z. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immunol. 70:2002;544-550
18. Little S.F., Ivins B.E., Fellows P.F., Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immunol. 65(12):1997;5171-5175
19. Reuveny S., White M.D., Adar Y.Y. et al. Search of correlates of protective immunity conferred by anthrax vaccine. Infect Immunol. 69(5):2001;2888-2893
20. Ivins B, Farchaus J, Novak J, et al. Vaccine efficacy of Bacillus anthracis protective antigen produced in prokaryotic and eukaryotic cells. In: Proceedings of the Abstract on 94th Annual Meeting of the American Society of Microbiology, vol. E-38; 1994. p. 150.
21. Worsham P.L., Sowers M.R. Isolation of an asporogenic (spoOA) protective antigen-producing strain of Bacillus anthracis. Can. J. Microbiol. 45:1999;1-8
22. Farchaus J.W., Ribot W.J., Jendrek S., Little S.F. Fermentation, purification, and characterization of protective antigen from a recombinant* avirulent strain of Bacillus anthracis. Appl. Environ. Microbiol. 64:1998;982-991
23. Lacy M.J., Voss E.W. Jr. A modified method to induce immune polyclonal ascites fluid in BALB/c mice using Sp2/0-Ag14 cells. J. Immunol. Meth. 87:1986;169-177
24. Bliss CI, Statistics in biology: statistical methods for research in the natural sciences. Linear regression. New York: McGraw-Hill; 1967. p. 152-85.
25. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Meth. 119:1989;203-210
26. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., Ingraham N.R. Field evaluation of a human anthrax vaccine. Am. J. Pub. Health. 52:1962;632-645
27. Reed D.S., Smoll J., Gibbs P., Little S.F. Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis. Cytometry. 49:2002;1-7
28. Welkos S.L., Friedlander A.M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microbiol. Pathol. 4:1988;53-69
29. Welkos S.L., Friedlander A.M. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microbiol. Pathol. 5:1988;127-139
30. Little S.F., Ivins B.E., Fellows P.F., Pitt M.L.M., Norris S.L.W., Andrews G.P. Defining a serological correlate of protection in rabbits for recombinant anthrax vaccine. Vaccine. 22:2004;422-430